Table 2 Ankle kinematics and stance duration analysis were carried out prior to nerve injury (wek-0), at week-2, and every 4 weeks during the 20-week follow-up period.
Temporal Parameter | Â | Week 0 | Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 |
|---|---|---|---|---|---|---|---|---|
IC | End-to-End | -194.15 ± 44.35 | -448.33 ± 66.25 | -604.86 ± 66.95 | -351.64 ± 73.81 | -639.43 ± 120.70 | -809.90 ± 88.67 | -647.63 ± 81.94 |
|  | End-to-EndMemb |  | -728.48 ± -297.40 | -785.62 ± -320.73 | -593.43 ± -242.26 | -234.56 ± -95.76 | -302.06 ± -123.31 | -514.54 ± -210.06 |
|  | End-to-EndMembCell |  | -557.10 ± 224.85 | -505.97 ± 108.58 | -845.50 ± 160.47 | -933.63 ± 57.41 | -914.05 ± 80.10 | -903.24 ± 74.55 |
OT | End-to-End | -270.35 ± 19.65 | -273.97 ± 47.92 | -385.24 ± 37.99 | -399.28 ± 34.85 | -530.42 ± 68.29 | -460.90 ± 66.08 | -414.22 ± 35.18 |
|  | End-to-EndMemb |  | -641.95 ± -262.08 | -528.60 ± -215.80 | -321.92 ± -131.42 | -449.49 ± -183.50 | -582.66 ± -237.87 | -411.32 ± -167.92 |
|  | End-to-EndMembCell |  | -357.80 ± 43.21 | -495.68 ± 82.13 | -372.17 ± 33.65 | -467.31 ± 76.14 | -471.29 ± 20.94 | -278.67 ± 20.71 |
HR | End-to-End | 53.25 ± 40.58 | -177.64 ± 41.45 | -246.61 ± 11.49 | -333.55 ± 16.41 | -280.20 ± 24.32 | -322.47 ± 18.46 | -322.86 ± 23.80 |
|  | End-to-EndMemb |  | -265.19 ± 28.15 | -301.10 ± 65.99 | -268.48 ± 64.92 | -114.06 ± 82.52 | -327.76 ± 86.17 | -222.91 ± 51.33 |
|  | End-to-EndMembCell |  | -353.02 ± 24.39 | -285.60 ± 21.13 | -190.41 ± 9.69 | -286.61 ± 57.54 | -283.54 ± 12.24 | -216.29 ± 21.36 |
TO | End-to-End | -221.38 ± 91.28 | 322.87 ± 109.64 | 327.44 ± 31.23 | 399.79 ± 82.70 | 403.59 ± 57.88 | 444.05 ± 78.95 | 193.03 ± 130.15 |
|  | End-to-EndMemb |  | 554.31 ± 69.27 | 384.52 ± 66.65 | 227.17 ± 123.13 | 281.98 ± 79.91 | 577.14 ± 155.51 | 311.14 ± 197.88 |
|  | End-to-EndMembCell |  | 248.78 ± 30.40 | 420.52 ± 28.58 | 355.25 ± 43.90 | 466.17 ± 43.54 | 551.88 ± 43.74 | 460.01 ± 51.01 |